We have a diversified and balanced portfolio covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

The company also has a vaccine platform discovering and developing glycoconjugate vaccines containing synthetic antigenic glycan molecules with and without a carrier protein to prevent infection.



Mechanism of action

Target indication


More Information

QUVIVIQ™   (daridorexant)

Dual orexin receptor antagonist


Commercially available in the US, Germany, Italy, and Switzerland;
approved in the EU, UK, and Canada;
filing in Japan expected H2 2023;
Phase 2 in pediatric insomnia – recruiting

Investor webcast


Dual endothelin receptor antagonist

Difficult-to-control (resistant) hypertension

NDA under review in the US, MAA under review in the EU, other filings in preparation

Investor webcast


Glucosylceramide synthase inhibitor

Fabry disease

Phase 3 primary endpoint not met, Open Label Extension study (OLE) ongoing



P2Y12 inhibitor

Suspected acute myocardial infarction

Phase 3 recruiting

Investor webcast


S1P1 receptor modulator

Systemic lupus erythematosus

Phase 3 recruiting

Investor webcast


ACKR3 / CXCR7 antagonist

Multiple sclerosis and other demyelinating diseases

Phase 2 in preparation



GBA2/GCS inhibitor

Rare lysosomal storage disorders

Phase 1 complete



C5aR1 antagonist

Immune-mediated disorders

Phase 1



CXCR3 antagonist

Recent-onset Type 1 diabetes

Phase 1




Immune-mediated disorders

Phase 1



Synthetic glycan vaccine

Clostridium difficile infection

Phase 1 in preparation


* In collaboration with Janssen Biotech.

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 was investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy. The study did not meet the primary endpoint. ACT-709478 was generally well tolerated. Neurocrine continues to analyze the data generated in the study.

On July 20, 2023, Idorsia sold its operating businesses in the Asia Pacific (ex-China) region to Sosei Heptares, including the assignment of the license for PIVLAZ (clazosentan) for the Asia Pacific (ex-China) region. Idorsia retains the rights to clazosentan in the rest of the world.

Innovation fact sheet

For investors, we provide more information on how Idorsia is innovating to change treatment paradigms in our innovation fact sheet. Please visit the investor section for more information.